

# Current issues on sublingual allergen-specific immunotherapy in children with asthma and allergic rhinitis

Zorica Živković<sup>1,2</sup>, Ivana Djurić-Filipović<sup>3,4</sup>, Snežana Živanović<sup>5</sup>

<sup>1</sup>Medical Center „Dr Dragiša Mišović“, Children’s Hospital for Lung Diseases and Tuberculosis, Belgrade, Serbia;

<sup>2</sup>University Business Academy in Novi Sad, Faculty of Pharmacy, Novi Sad, Serbia;

<sup>3</sup>Sanofi Pasteur, Belgrade Office, Belgrade, Serbia;

<sup>4</sup>University of Kragujevac, Faculty of Medical Sciences, Kragujevac, Serbia;

<sup>5</sup>Clinical Center, Clinic for Children’s Internal Diseases, Niš, Serbia

## SUMMARY

In 1993 the European Academy of Allergy and Clinical Immunology was the first official organization to recognize that sublingual administration could be “promising route” for allergic desensitization. A few years later, the World Health Organization recommended this therapy as “a viable alternative to the injection route in adults.” The first meta-analysis showed sublingual allergen specific immunotherapy (SLIT) effectiveness for allergic rhinitis and another study showed SLIT can actually help prevent the development of asthma both in adults and in children. The main goal of this review article is to present insight into the most up-to-date understanding of the clinical efficacy and safety of immunotherapy in the treatment of pediatric patients with allergic rhinitis and asthma. A literature review was performed on PubMed from 1990 to 2015 using the terms “asthma,” “allergic rhinitis,” “children,” “allergen specific immune therapy.” Evaluating data from double-blind placebo-controlled randomized clinical trials (DB-PC-RCTs), the clinical efficacy (assessed as the reduction of symptom score and the need of rescue medication) of SLIT for allergic rhinitis and allergic asthma, has been confirmed in various meta-analysis. Outcomes such as rhinoconjunctivitis score and medication scores, combined scores, quality of life, days with severe symptoms, immunological endpoints, and safety parameters were all improved in the SLIT-tablet compared with placebo group. SLIT safety has been already proven in many DB-PC-RCTs and real-life settings. In accordance with all of the above mentioned, the goals for future trials and studies are the development of comprehensive guidelines for clinical practice on immunotherapy, embracing all the different potential participants. The importance of allergen immunotherapy is of special relevance in the pediatric age, when the plasticity and modulability of the immune system are maximal, and when preventative effects can be reasonably expected.

**Keywords:** allergen immunotherapy; children; asthma; allergic rhinitis

## INTRODUCTION AND HISTORICAL BACKGROUND TO SUBLINGUAL IMMUNOTHERAPY

The first data concerning allergen immunotherapy (AIT) dates back to the beginning of the 20th century when Freeman and Noon were the first to use allergen extracts for desensitizing patients [1, 2]. Although the first clinical trials of allergen-specific sublingual immunotherapy to pollen date back to the 1920s [3], it was not used until the 1970s when interest in the mucosal route was re-examined by a group of German investigators who showed the clinical efficacy of sublingual allergen specific immunotherapy (SLIT) in comparison with subcutaneous allergen specific immunotherapy (SCIT) [4]. The next step in SLIT evolution was revealed by Scadding’s and Brostoff’s [5] double-blind placebo-controlled trial (DB-PCT) on SLIT efficacy [5]. At the same time, a group of Italian allergists investigated the sublingual manner of allergen administration in order to make this kind of therapy more available [6]. Early papers with sublingual allergen immunotherapy

demonstrated positive results, and in 1993 the European Academy of Allergy and Clinical Immunology was the first official organization to recognize that sublingual administration could be a “promising route” for allergic desensitization [7, 8]. A few years later, SLIT safety in adults and children (age >5) was shown [9, 10]. Based on eight DB-PCTs on clinical efficacy of SLIT drops, the World Health Organization recommended in 1998 that this therapy can be considered to be “a viable alternative to the injection route in adults” [11]. A recent Cochrane review analyzing symptoms and/or medication scores proved the efficacy of SLIT in 49 randomized control trials (RCTs) with 4,589 children and adults affected by allergic rhinitis (AR) (with or without asthma or conjunctivitis), compared with placebo [12].

The main goal of this review article is to present insight into the most up-to-date understanding of the clinical efficacy and safety of immunotherapy in the treatment of pediatric patients with allergic rhinitis and asthma. A literature review was performed on PubMed up until 2015 using MeSH terms “asthma,” “allergic

## Correspondence to:

Zorica ŽIVKOVIĆ  
Knežinje Zorke 9,  
11000 Belgrade  
Serbia  
zoricazivkovic@yahoo.com

rhinitis,” “children,” “immune therapy.” Additional articles were identified by a manual search of the list of references in the initial search.

## EPIDEMIOLOGY OF ASTHMA AND RHINITIS IN SERBIA

The list of articles analyzing the prevalence and epidemiology of childhood atopic diseases, mainly asthma, dermatitis, and rhinitis, is extremely long and extensive. The numbers varied from too low to too high mainly due to a great heterogeneity in the methodological and statistical background. However, the International Study of Asthma and Allergies Phase Three has valuable influence, involving 98 countries worldwide and 236 Phase Three Centers – in other words, it encompasses around 1,059,053 children of two age groups from 236 centers in 98 countries [13, 14]. The prevalence rate of allergic rhinitis, asthma, and eczema in Serbia has been investigated as a part of the International Study of Asthma and Allergies Phase Three. The survey was conducted in five regional centers with different geographical and urban characteristics. Around 14,000 children were enrolled, aged six to seven years and 13–14 years. Prevalence rate of asthma has been 6.59% in the six to seven years age group, and 5.36% in the 13–14 years age group. Prevalence of allergic rhinitis has been 7.17% in six to seven years age group, and 14.89% in the 13–14 years age group. In total, we found asthma in 5.91%, rhinitis in 11.46%, and eczema in 14.27% of the children [15].

## CLINICAL EFFICACY

Evaluating data from DB-PC-RCTs, the clinical efficacy (assessed as the reduction of symptom score and the need of rescue medication) of SLIT for allergic rhinitis and allergic asthma has been confirmed in various meta-analyses (Tables 1 and 2) [12, 16–19].

However, significant clinical and methodological heterogeneity was shown among studies and some issues are still a matter of debate. Recently, a study by Nelson et al.

[20], in addition to confirming clinical efficacy of SLIT in reducing nasal and ocular symptoms and the use of rescue medications, also observed no differences in clinical efficacy in mono- and poly-sensitized patients. The effect of disease modification of an SQ-standardized grass SLIT-tablet two years after three years of treatment has been shown in a randomized trial in patients with moderate-to-severe grass pollen induced rhinoconjunctivitis. Outcomes such as rhinoconjunctivitis score and medication scores, combined scores, quality of life, days with severe symptoms, immunological endpoints, and safety parameters were all improved in the SLIT-tablet, compared with placebo group [21]. Results from a 15-year-long prospective study by Marogna et al. [22] show that long-lasting effects of SLIT are in direct correlation with the treatment's duration. Analyzing 59 adult patients on SLIT, the authors concluded that four years of SLIT treatment is optimal to achieve long lasting effects. Duration of five years or more adds only non-additional benefits [22]. The SLIT approach in very young children has raised skepticism concerning the use of soluble allergen drops in an age group that cannot sufficiently hold sublingual allergen long enough under the tongue to deliver allergens to mucosal immune cells [23]. The current study might provide evidence that preventive SLIT over a treatment period of one to two years would deliver enough allergen as to mediate immunologic changes [24]. Nevertheless, optimizing allergen dosing and treatment duration for the use of preventive immunotherapy (sublingual or subcutaneous) in very young children is one of the main questions to be solved. Overall, the current pilot study underlines that the approach of immunomodulation by preventive allergen-specific immunotherapy in early infancy is feasible, and larger studies should delineate more details of optimal application modalities [25]. Literature data showed that SLIT can prevent the development of new sensitization, comparing with the standard pharmacotherapy, even six years after cessation of the treatment [26]. A study of sublingual immunotherapy done by Malling et al. [27] showed that the allergen used for immunotherapy is historically the predominant cause of symptoms, the beneficial effect of SLIT in polysensitized

**Table 1.** Comparison between SLIT studies

Symptom scores	Reference	Study population	Studies (N)	Active participants (n)	Placebo (n)	Heterogeneity (I <sup>2</sup> )
Rhinitis	Wilson D, 2003	Adults and children	21	484	475	73%
Rhinitis	Penagos M, 2006	Children	10	245	239	81%
Rhinitis	Radulović S, 2011	Adults and children	49	2,333	2,256	81%
Asthma	Calamita Z, 2006	Adults and children	9	150	153	64%
Asthma	Penagos M, 2008	Children	9	232	209	94%

Heterogeneity (I<sup>2</sup>) = 0–40%: might not be significant; 30–60%: may represent moderate heterogeneity; 50–90%: may represent substantial heterogeneity; 75–100%: considerable heterogeneity

**Table 2.** Medication score

Medication scores	Reference	Study population	Studies (N)	Active participants (n)	Placebo (n)	Heterogeneity (I <sup>2</sup> )
Rhinitis	Wilson D, 2003	Adults and children	17	405	398	44%
Rhinitis	Penagos M, 2006	Children	7	141	138	86%
Rhinitis	Radulović S, 2011	Adults and children	38	1,737	1,642	50%
Asthma	Calamita Z, 2006	Adults and children	6	132	122	92%
Asthma	Penagos M, 2008	Children	7	192	174	95%

participants is similar to that observed for monosensitized patients. This is of importance particularly in patients with respiratory allergies [27].

In the pediatric age range, allergic diseases represent a special problem, with specific aspects, that include their possible evolution (allergic march) [28–30], the problems related to the long-term pharmacotherapy [31], the compliance (which is in charge of caregivers), and the objective difficulties in correctly deliver inhaled drugs. In addition, the quality of life of the children themselves and of their parents (drug treatment, emergency unit visits, impaired school performance and absenteeism), is usually affected [32, 33].

On the other side, quality of life in children with asthma revealed poor score only for physical activities in children, while very poor score for parents and very high level of anxiety related to their children's asthma [34].

Many clinical trials and meta-analyses have convincingly demonstrated that AIT is effective in reducing symptoms and drug consumption, with a consequent improvement of the overall quality of life [35].

## CLINICAL INDICATIONS

Recommendations from various allergy organizations to minimize risk and improve efficacy suggest the following considerations for initiating immunotherapy: 1) demonstrating the presence of IgE-mediated disease – atopic constitution in early childhood; 2) documentation that specific sensitivity is involved in symptoms – positive *in vivo* tests on aeroallergens and *in vitro* tests minimum class three on aeroallergens; 3) documentation of the severity and duration of symptoms of allergic rhinitis and asthma [7]. The first dose should be taken in the presence of a doctor (observation period of 30–60 minutes). In this way, patients are reassured about the safety of SLIT, their follow-up can be organized, and compliance structured. SLIT drops or tablets are recommended to be taken usually for three years as continuous treatment during the year or pre- and co-seasonal treatment.

## SAFETY OF SLIT IN ALLERGIC CHILDREN

SLIT safety has been already proven in many DB-PC-RCTs and real-life settings [36].

Life-threatening and non-life-threatening severe systemic adverse events (SAEs) related to SLIT for allergic asthma, allergic rhinitis, or allergic rhino-conjunctivitis involving pediatric population are very rare even in DB-PC-RCTs. The prevalence of SAE was lower than 20%, whereas the prevalence of severe SAEs was between 1% and 2%, with only one study reported epinephrine use [37–39]. In real-life settings, most of the systemic reactions reported by post-marketing surveys were mild and resolved spontaneously without any treatment [40–45]. Potential risk factors for systemic adverse reactions are still confusing. Concerning the vaccine-related risk factors, the most relevant are the use of non-standardized extracts,

administration of products containing a mixture of many allergens, and overdosing [46]. On the other side, cardiovascular diseases and long-term therapy with non-cardio selective beta-blockers, as well as uncontrolled asthma, oral lesions, and infections can be marked as potential triggers of SAEs related to the patient [47, 48].

The most common SLIT-related local adverse events include oropharyngeal signs and symptoms and gastrointestinal reactions with great variability of their prevalence, rated between 50% and 85% [49, 50, 51].

## ORAL TOLERANCE

The immunological effects of SCIT have already been described in a great number of studies. Nevertheless, the questions on SLIT immune modulatory effects are strongly debated. It is well known that SLIT affects both humoral and cell-mediated immune responses. Concerning the allergen specific IgG4, it is proven that SLIT increases its level, although this effect is less intensive comparing with SCIT. The most important immunological effects of SLIT are reduction in mucosal infiltration by effector cells (neutrophils and eosinophils), increase in allergen-specific IL-10 production, and modulation in Th1 and Treg activity in the oral mucosa. The oral mucosa is described as a site of natural immune tolerance induction. Antigen presenting cells (APCs) in the oral mucosa were suggested to be the main actors for the modulation of IL-10 and TGF- $\beta$ -secreting Tregs observed following sublingual immunotherapy. After allergen uptake by specialized APCs in the oral mucosa, they migrate to regional lymph nodes. These professional APCs are characterized by the expression of high levels of MHCclass I and II, costimulatory molecules such as CD40, CD80, CD86, and high levels of the IgE receptor Fc $\epsilon$ RI. As mentioned before, these cells are able to release IL-10 in a TLR4-dependent manner and induce T-cells with a regulatory phenotype *in vitro*, after contact with allergen [52, 53].

## FUTURE PERSPECTIVES

Despite a great amount of DB-PC-RCTs and meta-analyses, there are no official guidelines on clinical practice on SLIT. In real life, detailed investigations (that have to be performed before the decision on immunotherapy) in children of preschool age are difficult due to poor cooperation of a child and its parents. Secondly, the lack of information and standardized protocols on allergen-specific immunotherapy among pediatricians, allergologists, and all relevant subspecialties make this situation even more complicated. As there is great interest for this kind of treatment, European Academy of Allergy and Clinical Immunology has launched a new project on Guidelines for Clinical Practice on Allergen-Specific Immunotherapy. The main goals for future trials and studies are the development of comprehensive guidelines for clinical practice on immunotherapy, embracing all the different potential

participants (i.e. clinicians, immunologists, GPs, allergen technologists, industry research department representatives, regulatory bodies, allied health representatives, and patient organizations) [54].

## CONCLUSION

Subcutaneous immunotherapy (SCIT), which remained the only administration route for several decades, is effective and safe when properly prescribed and administered, but remote risk of severe side effects is present. For this reason, the international guidelines consider the age below five years a relative contraindication to SCIT. In contrast, SLIT seems to be safe and is presently considered as a viable alternative option for traditional subcutaneous route. In addition to the safety profile, SLIT is also convenient because no injection is needed and it can be managed at home. Recently, a number of studies proved the efficacy of simplified schedule (short build-up and once daily dosing)

which have been introduced in order to make the SLIT even acceptable.

All of the above mentioned – proven clinical efficacy in a great number of studies in pediatric population, better safety profile comparing with SCIT (with the possibility of using it in children below the age of five years), disease modifying capability with the possibility of having the long-term effects – implicate that if we want to consider modern approach to allergic diseases, we have to take AIT into consideration. These facts take on special relevance in the pediatric age, when the plasticity and modulability of the immune system are maximal, and when preventative effects can be reasonably expected.

## ACKNOWLEDGEMENT

This study was supported by the Ministry of Education, Science and Technological Development of the Republic of Serbia, Grant No. III41004.

## REFERENCES

- Noon L. Prophylactic Inoculation against Hay Fever. *The Lancet*. 1911; 177:1572–3.
- Freeman J, Noon L. Further observation on the treatment of hay-fever by hypodermic inoculation of pollen vaccine. *Lancet*. 1911; 2:814–7.
- Black JH. The oral administration of pollen: clinical report. *J Lab Clin Med*. 1928; 13:709–13.
- Rebien W, Wahn U, Puttonen E, Maasch HG. Comparative study of immunological and clinical efficacy of oral and subcutaneous hyposensitization. *Allergologie*. 1980; 3:101–9.
- Scadding GK, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. *Clin Allergy*. 1986; 16(5):483–91. [PMID: 3536171]
- Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double blind study. *Allergol Immunopathol*. 1990; 18:277–84. [PMID: 2097894]
- Malling H, Weeke B. Immunotherapy. Position Paper of the European Academy of Allergy and Clinical Immunology. *Allergy*. 1993; 48(Suppl 14):39–5.
- Malling HJ, Abreu-Nogueira J, Alvarez-Cuesta E, Bjorksten B, Bousquet J, Caillotet D, et al. Position Paper of the European Academy of Allergy and Clinical Immunology on local immunotherapy. *Allergy*. 1998; 53:933–44. [PMID: 9821472]
- Di Rienzo V, Pagani A, Parmiani S, Passalacqua G, Canonica GW. Post-marketing surveillance study on the safety of sublingual immunotherapy in children. *Allergy*. 1999; 54:1110–3. [PMID: 10536891]
- Lombardi C, Gargioni S, Melchiorre A, Passalacqua G. Safety of sublingual immunotherapy in adults: a post marketing surveillance study. *Allergy*. 2001; 56:889–92. [PMID: 11576079]
- Bousquet J, Lockey R, Malling HJ. World Health Organization Position Paper. Allergen immunotherapy: therapeutical vaccines for allergic diseases. *Allergy*. 1998; 53:41–42.
- Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). *Allergy*. 2011; 66:740–52. [DOI: 10.1111/j.1398-9995.2011.02583.x] [PMID: 21443635]
- Ait-Khaled N, Pearce N, Anderson HR, Ellwood P, Montefort S, Shah J, and the ISAAC Phase Three Study Group. Global map of the prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three. *Allergy*. 2009; 64:123–148. [DOI: 10.1111/j.1398-9995.2008.01884] [PMID: 19132975]
- Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S. International study of asthma and allergies in childhood phase three study group. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). *Thorax*. 2009; 64:476–83. [DOI: 10.1136/thx.2008.106609] [PMID: 19237391]
- Zivkovic Z, Vukasinovic Z, Cerovic S, Radulovic S, Zivanovic S, Panic E, et al. Prevalence of childhood asthma and allergies in Serbia and Montenegro. *World J Pediatr*. 2010; 6(4):331–6. [DOI: 10.1007/s12519-010-0207-y] [PMID: 20549414]
- Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis. *Cochrane Database Syst Rev*. 2003; (2):CD002893.
- Penagos M, Compalati E, Tarantini F, Baena-Cagnani R, Huerta J, Passalacqua G, et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. *Ann Allergy Asthma Immunol*. 2006; 97:141–148. [DOI: 10.1016/S1081-1206(10)60004-X]
- Calamita Z, Saconato H, Pelá AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. *Allergy*. 2006; 61(10):1162–72. [DOI: 10.1111/j.1398-9995.2006.01205.x]
- Penagos M, Passalacqua G, Compalati E, Baena-Cagnani CE, Orozco S, Pedroza A, et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. *Chest*. 2008; 133:599–609. [PMID: 17951626]
- Nelson H, Blaiss M, Nolte H, Wu'rtz SØ, Andersen JS, Durham SR. Efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet in mono- and polysensitized subjects. *Allergy*. 2013; 68:252–255. [PMID: 23205670] [DOI: 10.1111/all.12074]
- Durham R, Emminger W, Kapp A, Monchy JGR, Rak S, Scadding GK, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. *J Allergy Clin Immunol*. 2012; 129:717–725. [DOI: 10.1016/j.jaci.2011.12.973] [PMID: 22285278]
- Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. *J Allergy Clin Immunol*. 2010; 126(5):969–75. [DOI: 10.1016/j.jaci.2010.08.030] [PMID: 20934206]
- Holt PG, Sly PD, Sampson HA, Robinson P, Loh R, Lowenstein H, et al. Prophylactic use of sublingual allergen immunotherapy in high-risk children: a pilot study. *J Allergy Clin Immunol*. 2013; 132(4):991–3.e1. [DOI: 10.1016/j.jaci.2013.04.049] [PMID: 23768574]
- Shamji MH, Durham SR. Mechanisms of immunotherapy to aeroallergens. *Clin Exp Allergy*. 2011; 41:1235–46. [DOI: 10.1111/j.1365-2222.2011.0380] [PMID: 21762223]



25. Szépfalusi Z, Bannert C, Ronceray L, Mayer E, Hassler M, Wissmann E, et al. Preventive sublingual immunotherapy in preschool children: first evidence for safety and pro-tolerogenic effects. *Pediatr Allergy Immunol.* 2015; 25:788–795. [DOI: 10.1111/pai.12310] [PMID: 25406682]
26. Eng PA, Borer-Reinhold M, Heijnen IAFM, Gnehm HPE. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. *Allergy.* 2006; 61:198–01. [PMID: 16409196]
27. Malling HJ, Montagut A, Melac M, Patriarca G, Panzner P, Seberova E, et al. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis. *Clin Exp Allergy.* 2009; 39(3): 387–93. [DOI: 10.1111/j.1365-2222.2008.03152.x] [PMID: 19134019]
28. Linneberg A. The allergic march in early childhood and beyond. *Clin Exp Allergy.* 2008; 38:1419–21. [DOI: 10.1111/j.1365-2222.2008.03063.x] [PMID: 18631352]
29. Burgess JA, Lowe AJ, Matheson MC, Varigos G, Abramson MJ, Dharmage SC. Does eczema lead to asthma? *J Asthma.* 2009; 46:429–36. [DOI: 10.1080/02770900902846356] [PMID: 19544160]
30. Živković Z, Cerović S, Vukasinović Z, Jocić-Stojanović J. News in treatment of childhood asthma. *Srp Arh Celok Lek.* 2009; 137(9-10):558–61. [DOI: 10.2298/SARH0910558Z] [PMID: 19950768]
31. Bousquet J, Schünemann HJ, Zuberbier T, Bachert C, Baena-Cagnani CE, Bousquet PJ, et al. Development and implementation of guidelines in allergic rhinitis-an ARIA-GA2LEN paper. *Allergy.* 2010; 65:1212–21. [DOI: 10.1111/j.1398-9995.2010.02480.x] [PMID: 20887423]
32. Cerović S, Živković Z, Milenković B, Jocić-Stojanović J, Opancina-Bajec A, Vukasinović Z. The Serbian Version of the Pediatric Asthma Quality of Life Questionnaire in Daily Practice. *J Asthma.* 2009; 46:936–9. [DOI: 10.3109/02770900903265812] [PMID: 19905922]
33. Živković Z, Radić S, Cerović S, Vukašinović Z. Asthma school program in children and their parents. *World J Pediatr.* 2008; 4:267–73. [DOI: 10.1007/s12519-008-0049-z] [PMID: 19104890]
34. Calderon MA, Demoly P, Gerth van Wijk R, Bousquet J, Sheikh A, Frew A, et al. EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. *Clinical and translational allergy.* 2012; 2:20. Available online at: <http://www.ctajournal.com/content/2/1/20>. [DOI: 10.1186/2045-7022-2-20] [PMID: 23110958]
35. Djuric-Filipovic I, Caminati M, Kostic G, Filipovic Dj, Živkovic Z. An update of allergen specific sublingual immunotherapy in children with asthma and allergic rhinitis. *World J Pediatr.* 2016; 2(3):283–290. [DOI: 10.1007/s12519-016-0022-1]
36. Lin SY, Erekosima N, Kim JM, Ramanathan M, Suarez-Cuervo C, Chelladurai Y, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma. *J Am Med Assoc.* 2013; 309:1278–1288. [DOI: 10.1001/jama.2013.2049] [PMID: 23532243]
37. Yukselen A, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study. *Int Arch Allergy Immunol.* 2012; 157:288–298. [DOI: 10.1159/000327566] [PMID: 22041501]
38. Aydogan M, Eifan AO, Keles S, Akkoc T, Nursoy MA, Bahceciler NN, et al. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial. *Respir Med.* 2013; 107:1322–1329. [DOI: 10.1016/j.rmed.2013.06.021] [PMID: 23886432]
39. Blaiss M, Maloney J, Nolte H. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. *J Allergy Clin Immunol.* 2011; 127:64–71. [DOI: 10.1016/j.jaci.2010.11.034] [PMID: 21211642]
40. de Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immuno-therapy with grass pollen tablets. *Allergy.* 2009; 64:963–964. [DOI: 10.1111/j.1398-9995.2009.01998.x]
41. Di Rienzo V, Pagani A, Parmiani S, Passalacqua G, Canonica GW. Postmarketing surveillance study on the safety of sublingual immunotherapy in children. *Allergy.* 1999; 54:1110–1113. [DOI: 10.1034/j.1398-9995.1999.00267]
42. Drachenberg KJ, Urban E, Proll S, Woroniecki SR. Sublingual specific immunotherapy for adults and children: a post marketing surveillance study. *Allergol Immunopathol.* 2004; 32:76–81. [PMID: 15087094]
43. Agostinis F, Tellarini R, Canonica GW, Falagiani P, Passalacqua G. Safety of sublingual immunotherapy with a monomeric allergoid in very young children. *Allergy.* 2005; 60:133. [DOI: 10.1111/j.1398-9995.2004.00616.x]
44. Rienzo VD, Minelli M, Musarra A, Sambugaro R, Pecora S, Canonica WG, et al. Post marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. *Clin Exp Allergy.* 2005; 35:560–564. [DOI: 10.1111/j.1365-2222.2005.02219.x] [PMID: 15898975]
45. Fiocchi A, Pajno G, La Grutta S, Pezzuto F, Incorvaia C, Sensi L, et al. Safety of SLIT in children aged 3 to 7 years. *Ann Allergy Asthma Immunol.* 2005; 95:254–258. [DOI: 10.1016/S1081-1206(10)61222-7] [PMID: 16200816]
46. Agostinis F, Foglia C, Landi M, Cottini M, Lombardi C, Canonica GW, et al. The safety of sublingual immunotherapy with one or multiple pollen allergens in children. *Allergy.* 2008; 63:1637–1639. [DOI: 10.1111/j.1398-9995.2008.01742.x]
47. De Castro G, Zicai AM, Indinnimeo L, Tancredi G, di Coste A, Occasi F, et al. Efficacy of sublingual immunotherapy on allergic asthma in children's real life. *Eur Rev Med Pharmacol Sci.* 2013; 17:2225–2231.
48. Caminati M, Dama A, Schiappoli M, Senna G. Balancing efficacy against safety in sublingual immunotherapy with inhalant allergens: what is the best approach? *Expert Rev Clin Immunol.* 2013; 9(10):937–47. [DOI: 10.1586/1744666X.2013.837262] [PMID: 24099148]
49. Calderon MA, Simons FER, Malling HJ, Lockey RF, Moingeon P, Demoly P. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. *Allergy.* 2012; 67(3):302–311. [DOI: 10.1111/j.1398-9995.2011.02761.x]
50. Passalacqua G, Canonica GW. Specific immunotherapy in asthma: efficacy and safety. *Clin. Exp. Allergy.* 2011; 41(9):1247–1255. [DOI: 10.1111/j.1365-2222.2010.03688.x] [PMID: 21255159]
51. Medical Dictionary for Regulatory Activities (MedDRA). Maintenance support services and organization. <http://www.meddrasso.com/>. [Accessed Oct 2014]
52. Piconi S, Trabattoni D, Rainone V, Borgonovo L, Passerini S, Rizzardini G, et al. Immunological effects of sublingual immunotherapy: clinical efficacy is associated with modulation of programmed cell death ligand 1, IL-10, and IgG4. *J Immunol.* 2010; 185:7723–30. [DOI: 10.4049/jimmunol.1002465] [PMID: 21076061]
53. Moingeon P. Update on immune mechanisms associated with sublingual immunotherapy: practical implications for the clinician. *J Allergy Clin Immunol Pract.* 2013; 1:228–41. [DOI: 10.1016/j.jaip.2013.03.013] [PMID: 24565479]
54. Caminati M, Durić-Filipović I, Arasi S, Peroni DG, Živković Z, Senna G. Respiratory allergies in childhood: recent advances and future challenges. *Pediatr Allergy Immunol.* 2015. [DOI: 10.1111/pai.12509] [PMID: 26582212]

## Актуелни проблеми у сублингвалној алерген-специфичној имунотерапији код деце са астмом и алергијским ринитисом

Зорица Живковић<sup>1,2</sup>, Ивана Ђурић-Филиповић<sup>3,4</sup>, Снежана Живановић<sup>5</sup>

<sup>1</sup>Клиничко-болнички центар „Др Драгиша Мишовић“, Дечја болница за плућне болести и туберкулозу, Београд, Србија;

<sup>2</sup>Универзитет „Привредна академија у Новом Саду“, Фармацеутски факултет, Нови Сад, Србија;

<sup>3</sup>Sanofi Pasteur, представништво у Београду, Београд, Србија;

<sup>4</sup>Универзитет у Крагујевцу, Факултет медицинских наука, Крагујевац, Србија;

<sup>5</sup>Клинички Центар Ниш, Клиника за дечје интерне болести, Ниш, Србија

### КРАТАК САДРЖАЈ

Године 1993. Европско удружење алерголога и клиничких имунолога препознало је сублингвални пут примене алергена као „обећавајући“ у процесу десензибилизације на алергене. Неколико година касније Светска здравствена организација (СЗО) препоручује овај вид терапије као „алтернативу“ инјекционом путу примене алергена код адултних пацијената. Прва метаанализа показује ефикасност сублингвалне алерген-специфичне имунотерапије (СЛИТ) код пацијената са алергијским ринитисом, док је једна друга студија потврдила да СЛИТ може успешно да превенира развој астме код деце и одраслих са алергијским ринитисом. Главни циљ овог ревијалног рада је да презентује најновија знања и ставове на тему клиничке ефикасности и сигурности имунотерапије у лечењу педијатријских пацијената са алергијским ринитисом и астмом. Истраживање је извршено претрагом радова у базама *MEDLINE* и *PubMed* у периоду од 1990. до 2015. године користећи кључне речи астма, алергијски ринитис, деца и алерген-специфична имунотерапија. Већ од педијатријског узраста АИТ има посебно место у дечјем узрасту када су пластицитет и способност модулације имунског система максимални и када је оправдано очекивати значајан

превентивни ефекат. Анализирајући резулате двоструко слепо плацебо контролисаних рандомизираних клиничких студија (на основу смањења симптома скором и употребе спасоносних лекова), ефикасност СЛИТ-а је показана у великом броју метаанализа. Резултати као што су риноконјунктивитис скор, лек скор, симптом-лек скор, квалитет живота, број дана са тешким симптомима, имунолошки параметри, сигурносни профил били су значајно бољи у групи пацијената који су били на сублингвалној алерген-специфичној имунотерапији у односу на пацијенте који су били на плацебу. Сигурност СЛИТ-а је показана у бројним двоструко слепо плацебо контролисаним студијама и *real life* студијама. У складу са свим претходно поменутиим, главни циљеви будућих истраживања треба да се фокусирају на развој јасних водича за клиничку примену сублингвалне алерген-специфичне имунотерапије, укључујући знања и потенцијале различитих специјалиста. Алерген-специфична имунотерапија у педијатријском узрасту је нарочито важна зато што је пластицитет и модулабитет имунског система тада највећи, као и очекивани превентивни ефекти ове терапије.

**Кључне речи:** алерген-специфична имунотерапија; деца; астма; алергијски ринитис

Примљен • Received: 19/06/2015

Ревизија • Revision: 30/11/2015

Прихваћен • Accepted: 07/12/2015